GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Cyclically Adjusted PB Ratio

Infant Bacterial Therapeutics AB (OSTO:IBT B) Cyclically Adjusted PB Ratio : 1.35 (As of Jul. 19, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Cyclically Adjusted PB Ratio?

As of today (2025-07-19), Infant Bacterial Therapeutics AB's current share price is kr48.30. Infant Bacterial Therapeutics AB's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec24 was kr35.67. Infant Bacterial Therapeutics AB's Cyclically Adjusted PB Ratio for today is 1.35.

The historical rank and industry rank for Infant Bacterial Therapeutics AB's Cyclically Adjusted PB Ratio or its related term are showing as below:

OSTO:IBT B' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.34
Current: 1.34

During the past 11 years, Infant Bacterial Therapeutics AB's highest Cyclically Adjusted PB Ratio was 1.34. The lowest was 0.00. And the median was 0.00.

OSTO:IBT B's Cyclically Adjusted PB Ratio is ranked better than
53.54% of 678 companies
in the Biotechnology industry
Industry Median: 1.66 vs OSTO:IBT B: 1.34

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Infant Bacterial Therapeutics AB's adjusted book value per share data of for the fiscal year that ended in Dec24 was kr12.639. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr35.67 for the trailing ten years ended in Dec24.

Shiller PE for Stocks: The True Measure of Stock Valuation


Infant Bacterial Therapeutics AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Cyclically Adjusted PB Ratio Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 2.60 1.50

Infant Bacterial Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 1.50 -

Competitive Comparison of Infant Bacterial Therapeutics AB's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Cyclically Adjusted PB Ratio falls into.


;
;

Infant Bacterial Therapeutics AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Infant Bacterial Therapeutics AB's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=48.30/35.67
=1.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infant Bacterial Therapeutics AB's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec24 is calculated as:

For example, Infant Bacterial Therapeutics AB's adjusted Book Value per Share data for the fiscal year that ended in Dec24 was:

Adj_Book=Book Value per Share/CPI of Dec24 (Change)*Current CPI (Dec24)
=12.639/132.9872*132.9872
=12.639

Current CPI (Dec24) = 132.9872.

Infant Bacterial Therapeutics AB Annual Data

Book Value per Share CPI Adj_Book
201512 22.801 100.276 30.239
201612 17.185 102.022 22.401
201712 22.901 103.793 29.343
201812 49.592 105.912 62.270
201912 45.466 107.766 56.107
202012 39.208 108.296 48.147
202112 35.209 112.486 41.626
202212 29.548 126.365 31.096
202312 22.653 131.912 22.838
202412 12.639 132.987 12.639

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Infant Bacterial Therapeutics AB  (OSTO:IBT B) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Infant Bacterial Therapeutics AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines